<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e>) is a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> of the lymphatic system with an incidence of 2-3/100.000/year in developed countries </plain></SENT>
<SENT sid="1" pm="."><plain>With modern multi-agent chemotherapy protocols optionally combined with radiotherapy (RT), 80% to 90% of <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> patients achieve long-term remission and can be considered cured </plain></SENT>
<SENT sid="2" pm="."><plain>However, current standard approaches bear a considerable risk for the development of treatment-related late effects </plain></SENT>
<SENT sid="3" pm="."><plain>Thus, one major focus of current clinical research in <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> is reducing the incidence of these late effects that include <z:hpo ids='HP_0001635'>heart failure</z:hpo>, <z:hpo ids='HP_0000789'>infertility</z:hpo>, <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:mp ids='MP_0002899'>fatigue</z:mp> and therapy-related <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="4" pm="."><plain>In previous analyses, t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after treatment for <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> was associated with a poor prognosis </plain></SENT>
<SENT sid="5" pm="."><plain>Nearly <z:hpo ids='HP_0000001'>all</z:hpo> patients died rapidly after diagnosis </plain></SENT>
<SENT sid="6" pm="."><plain>However, more recent analyses indicated an improved outcome among patients with t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> who are eligible for modern anti-leukemic treatment and allogeneic stem cell transplantation (aSCT) </plain></SENT>
<SENT sid="7" pm="."><plain>This article gives an overview of recent reports on the incidence and the treatment of t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/t-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> after <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">HL</z:e> therapy and describes the efforts currently made to reduce the risk to develop this severe late effect </plain></SENT>
</text></document>